Insider Transactions in Q1 2022 at Cerus Corp (CERS)
Insider Transaction List (Q1 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 14
2022
|
Chrystal Menard Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
30,307
-5.93%
|
$151,535
$5.04 P/Share
|
|
Mar 14
2022
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
28,513
-3.44%
|
$142,565
$5.04 P/Share
|
|
Mar 14
2022
|
Richard J Benjamin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
30,307
-5.67%
|
$151,535
$5.04 P/Share
|
|
Mar 14
2022
|
Kevin Dennis Green Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
32,102
-3.9%
|
$160,510
$5.04 P/Share
|
|
Mar 14
2022
|
Laurence M Corash Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
30,307
-0.48%
|
$151,535
$5.04 P/Share
|
|
Mar 14
2022
|
Vivek K Jayaraman Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
41,734
-3.85%
|
$208,670
$5.04 P/Share
|
|
Mar 14
2022
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
165,021
-2.78%
|
$825,105
$5.04 P/Share
|
|
Mar 12
2022
|
Chrystal Menard Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,437
+13.82%
|
-
|
|
Mar 12
2022
|
Carol Moore SVP Reg. & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
79,437
+8.54%
|
-
|
|
Mar 12
2022
|
Richard J Benjamin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,437
+13.31%
|
-
|
|
Mar 12
2022
|
Kevin Dennis Green Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
89,437
+9.68%
|
-
|
|
Mar 12
2022
|
Laurence M Corash Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
84,437
+1.31%
|
-
|
|
Mar 12
2022
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
112,900
+9.39%
|
-
|
|
Mar 12
2022
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
320,695
+5.1%
|
-
|
|
Mar 04
2022
|
Jami K Nachtsheim Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,127
+10.05%
|
-
|
|
Mar 01
2022
|
Richard J Benjamin Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+29.0%
|
-
|
|
Mar 01
2022
|
Laurence M Corash Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+2.13%
|
-
|
|
Mar 01
2022
|
Kevin Dennis Green Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+23.89%
|
-
|
|
Mar 01
2022
|
Vivek K Jayaraman Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90,000
+23.18%
|
-
|
|
Mar 01
2022
|
Chrystal Menard Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,500
+30.3%
|
-
|
|
Mar 01
2022
|
Carol Moore SVP Reg. & Quality |
BUY
Grant, award, or other acquisition
|
Direct |
45,000
+16.46%
|
-
|
|
Mar 01
2022
|
William Mariner Greenman President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
217,500
+10.72%
|
-
|
|
Feb 25
2022
|
William Mariner Greenman President and CEO |
SELL
Open market or private sale
|
Direct |
308,263
-8.41%
|
$1,541,315
$5.71 P/Share
|
|
Feb 25
2022
|
William Mariner Greenman President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
380,000
+16.65%
|
$1,140,000
$3.75 P/Share
|
|
Jan 03
2022
|
Carol Moore SVP Reg. & Quality |
SELL
Open market or private sale
|
Direct |
19,059
-9.51%
|
$133,413
$7.0 P/Share
|
|
Jan 03
2022
|
Carol Moore SVP Reg. & Quality |
BUY
Exercise of conversion of derivative security
|
Direct |
19,059
+8.69%
|
$57,177
$3.66 P/Share
|